Opendata, web and dolomites

SpheroPredict

A 3D advanced test for prediction of drug response in secondary liver cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SpheroPredict project word cloud

Explore the words cloud of the SpheroPredict project. It provides you a very rough idea of what is the project "SpheroPredict" about.

cancers    patients    locations    spheroid    solution    accurate    tumour    body    21st    metastatic    entail    deaths    warrant    created    micro    patient    treatments    clear    personalised    3d    primary    heterogeneous    individualised    cycle    options    treatment    platform    century    de    predict    life    urgent    cells    productivity    therapies    trial    worldwide    dealing    alleviate    era    guideline    therapy    international    financial    inefficient    chemotherapy    commercial    proven    liver    line    drugs    quality    time    incurred    guidelines    causes    biologically    migrating    published    treat    tumours    economic    secondary    regarding    perspectives    cancer    survival    deathliest    death    efficient    burden    drug    risked    lack    spheropredict    medicine    toxicity    model    risk    first    diseases    innovative    spherotec    commercialisation    chemoresistance    installing    designed    healthcare    error    efficacy    fail    metastasizing    feasibility    types   

Project "SpheroPredict" data sheet

The following table provides information about the project.

Coordinator
SPHEROTEC GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: MARTINSRIED
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.spherotec.com/ - www.spheromed.com - www.spheroselect.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPHEROTEC GMBH DE (MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPHEROPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPHEROPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More